Skip to content
Top Menu
  • Log In
  • Register
  • Facebook
  • Twitter
  • LinkedIn
MyChesCo

MyChesCo

Chester County News and Community Website

  • Communities
    • Avondale
    • Berwyn
    • Coatesville
    • Cochranville
    • Devon
    • Downingtown
    • Exton
    • Honey Brook
    • Kennett Square
    • Malvern
    • Oxford
    • Paoli
    • Parkesburg
    • Phoenixville
    • Spring City
    • Toughkenamon
    • West Chester
    • West Grove
  • Education
    • Chester County Intermediate Unit
    • School Districts
      • Avon Grove School District
      • Coatesville Area School District
      • Downingtown Area School District
      • Great Valley School District
      • Kennett Consolidated School District
      • Octorara Area School District
      • Owen J. Roberts School District
      • Oxford Area School District
      • Phoenixville Area School District
      • Spring-Ford Area School District
      • Tredyffrin-Easttown School District
      • Twin Valley School District
      • Unionville-Chadds Ford School District
      • West Chester Area School District
    • Charter Schools
    • Independent Schools
    • Colleges and Universities
    • Chester County Library System
  • News
    • Traffic
    • Weather
    • Business
    • Health / Medical
    • National
    • Pennsylvania
    • Sports
  • Entertainment
  • Lifestyle
  • Events
  • Tools
    • Members
    • Groups
    • Add/Edit Event
    • My Bookings
      • Manage Bookings
    • Submit an Article
    • Contact Us
    • Signup for Newsletter
    • Contests and Giveaways
    • Gas Prices
    • Register
    • Log In
  • About
    • MyChesCo
    • Writing for Us
    • Advertising with Us
    • Contacting Us
    • Citizen Journalism
    • Submitting Articles
    • Starting a Group
    • How to Support Us
    • Terms of Service
    • Privacy Policy
    • DMCA Policy
  • COVID-19

Fragile X syndrome

Zynerba Pharmaceuticals
Products and Services

Zynerba Pharmaceuticals Provides Regulatory Update on Zygel™ in Fragile X Syndrome

December 18, 2020December 18, 2020 - by MyChesCo

DEVON, PA — Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, has provided an update on its meeting with …

Read More

Zynerba Pharmaceuticals
Finance

Zynerba Pharmaceuticals Reports Third Quarter 2020 Financial Results and Operational Highlights

November 10, 2020November 10, 2020 - by MyChesCo

DEVON, PA — Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) has reported financial results for the third quarter ended September 30, 2020, and provided an overview of recent operational highlights.

Read More
Zynerba Pharmaceuticals
Public Companies

Zynerba Pharmaceuticals Provides Update on Recent Milestones

September 15, 2020September 15, 2020 - by MyChesCo

DEVON, PA — Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, provided an update on its Fragile X syndrome …

Read More

Zynerba Pharmaceuticals
Products and Services / Research

Zynerba Pharmaceuticals to Present an Update on the Zygel™ Development Program

July 23, 2020July 23, 2020 - by MyChesCo

DEVON, PA — Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, recently presented an overview of its Zygel™ (ZYN002) …

Read More
Zynerba Pharmaceuticals
Products and Services / Research

Zynerba Pharmaceuticals Announces Top Line Results from Pivotal CONNECT-FX Trial of Zygel™ (CBD Gel) in Fragile X Syndrome

July 1, 2020June 30, 2020 - by MyChesCo

DEVON, PA — Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced top line results from the 14-week …

Read More

Fragile X Syndrome
Research

Zynerba Pharmaceuticals Announces the Completion of Enrollment in the Pivotal CONNECT-FX Trial of Zygel™ in Fragile X Syndrome

February 28, 2020February 27, 2020 - by MyChesCo

DEVON, PA — Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, announced that the Company has completed enrollment in its 14-week …

Read More

Most Read

  • IRS, Treasury Disburse 2 Million more Economic Impact Payments
  • Stolen Vehicle Suspect Arrested in Chester City
  • Police Ask for Help Identifying Shoplifting Suspect
  • 4AM Hospitality Opens Letty’s Tavern in Kennett Square
  • National Sports and Events Center Moves Closer to Fruition in Coatesville
  • IRS Free File Can Help People with No Filing Requirement Find Overlooked Tax Credits, Get a Refund

Subscribe for Updates

Chester County Events

  • Invasive plant removal, Goose Creek
    • 04/17/2021
  • Chance McCoy (of Old Crow Medicine Show)
    • 04/22/2021
      Wayne
  • Cinco De Mayo Bar Crawl West Chester
    • 05/01/2021
      West Chester
  • Pennhurst
    • 05/01/2021 - 05/02/2021
      Spring City
  • Phoenixville Beer & Wine Festival 2021
    • 05/08/2021
      Phoenixville
  • all events

Follow Us

  • Facebook
  • Twitter
  • LinkedIn

Tools

  • Members
  • Newsletter
  • Events
  • Groups
  • Guest Articles
  • Coupon Center
  • Gas Prices
  • Log In
  • Register

About Us

  • About MyChesCo
  • Advertise
  • Contact Us
  • Support Us
  • Write for Us
  • Terms of Service
  • Privacy Policy
  • DMCA Policy

Recommended Reading

  • Overnight Lane Restrictions Planned for U.S. 30, Exton Bypass in West Whiteland Township
  • AMETEK Announces First Quarter 2021 Earnings Call
  • April 16 COVID-19 Update: 342,291 Vaccinations to Date in Chester County
  • Two Arrested for Shooting into Occupied Home in Kennett Square
  • Chester County Receives Grant to Help Address Gaps in Southern Chester County Internet Access
Copyright © 2021 MyChesCo.